An overview of sulbactam-durlobactam approval and implications in advancing therapeutics for hospital-acquired and ventilator-associated pneumonia by acinetobacter baumannii-calcoaceticus complex: A narrative review.

Ayush AnandAmogh VermaSarabjeet KaurPriyangi KathayatRachel M ManojAakanksha AakankshaJustice K TurzinPrakasini SatapathyMahalaqua N KhatibShilpa GaidhaneQuazi S ZahiruddinNeelima KukretiSarvesh RustagiArihant Surana

Published in: Health science reports (2024)

The combination of sulbactam and durlobactam is a promising treatment option for HAP and VAP caused by ABC complex.

Keyphrases

acinetobacter baumannii
multidrug resistant
drug resistant
pseudomonas aeruginosa
healthcare
small molecule
cystic fibrosis
adverse drug
intensive care unit
combination therapy
acute care